44 results about "Clostridium perfringens toxoid" patented technology

The invention relates to non-toxic tetanus toxin and clostridium perfringens beta toxin recombined fusion protein. By means of codon optimization, clostridium tetani fragments C and the recombined fusion protein containing multiple clostridium perfringens beta toxin mutants with amino acid mutation, the immunogenicity of two kinds of toxin protein is reserved to the maximum extent, and potential biosafety hazards caused by single amino acid mutation are avoided. The recombined fusion protein can be used for preparing unit vaccines of clostridium tetani, B type clostridium perfringens and C type clostridium perfringens; compared with a current commercial clostridium natural toxin inactivated vaccine in China, the recombined fusion protein has the advantages of being simple in preparation process, low in immunizing dose, excellent in vaccine potency and the like, the biosafety risk in the vaccine production process are greatly reduced, and the recombined fusion protein is an ideal candidate vaccine antigen for upgrading and updating the three kinds of clostridium toxin vaccines. When the recombined fusion protein is used for preparing a combined vaccine with other antigens, the combined vaccine can be prepared without increasing the use dose of the combined vaccine.

The invention discloses a humanized single-chain antibody 7D of Clostridium perfringens α toxin, which is screened from the phage antibody library Source bioscience, and is a fully human anti-Clostridium perfringens α toxin antibody, which can be realized Neutralizing the therapeutic effect of toxins, while overcoming various side effects of heterologous antibodies, eliminating the cumbersome steps and high cost of humanized transformation of heterologous antibodies, due to the small molecular weight of single-chain antibodies and strong penetrating ability in vivo, It quickly reaches damaged tissues and cells to play an anti-toxin effect, thus achieving the dual purpose of economy and high efficiency. The α-toxin has certain homology with other types of toxins of Clostridium perfringens, and the antibody drug may have inhibitory and therapeutic effects on other types of toxins, and can also be used as a detection reagent to detect α-toxins of Clostridium perfringens.

The invention relates to a Clostridium perfringens epsilon toxin recombinant subunit vaccine and a production method thereof. The Clostridium perfringens epsilon toxin recombinant subunit vaccine prepared by the present invention is produced by codon-optimized recombinant Clostridium perfringens epsilon toxin protein containing 3 amino acid mutations, that is, the natural toxin protein is retained to the greatest extent Integrity and spatial conformation, thereby maintaining its immunogenicity, and avoiding the biological safety hazards caused by single amino acid mutations. The vaccine also has the advantages of simple preparation process, low immune dose, and much higher vaccine efficacy than existing vaccines. Compared with the current commercialized Clostridium perfringens natural toxin inactivated vaccine in China, the biological safety in the vaccine production process is greatly reduced. It is an ideal candidate vaccine for upgrading the current type D Clostridium perfringens toxin vaccine in my country; and when preparing a combined vaccine with other antigens, the combined vaccine can be prepared without increasing the dosage of the combined vaccine.